 |
FDA Approval Activities for this Drug
Maxalt (rizatriptan benzoate) Tablets & Maxalt-MLT (orally disintegrating tablet), 5 and 10 mg, Merck NDA 20-864/S8 & 20-865/S9 4/22/02 5/2/02
Maxalt (rizatriptan benzoate) Tablets & Maxalt-MLT (orally disintegrating tablet), 5 and 10 mg, Merck NDA 20-864 & 20-865 6/29/98 6/30/98 6/30/98 4/8/99
Maxalt Indication: Migraine
Maxalt (rizatriptan)5 and 10 mg, . Merck & Co., NDA 20-865/S-001
NDA 20-864/S-003
For the latest approval information, please locate this drug using this index.
|